Search tips
Search criteria

Results 1-3 (3)

Clipboard (0)
Year of Publication
Document Types
1.  Critical study of Jara (aging) and its management 
Ayu  2012;33(2):264-269.
Jara Avastha (stage of old age) is the later phase of life in which maximum decline of bodily elements is observed. Paramanuvibhaga (cell division) takes place at every moment; particularly in old age, it will be fast in comparison with other phases of life. Some organ related changes also take place during this period, which are the decades of Balya, Vridhhi, Chhavi, Medha, Twak, etc., In this study, applied aspects of Medha Hani, Twak Hani, and Drishti Hani were evaluated subjectively as well as objectively. Patients were selected from the OPD of Department of Basic Principles, I.P.G.T. and R.A., Gujarat Ayurved University, Jamnagar, irrespective of their sex, caste, religion, etc., and randomly divided into two groups. Patients in Group A were treated with Panchagavya Ghrita and Group B with plain Go Ghrita for 90 days and the dose of drug was 10 g/day at Nirannakala (early morning with empty stomach). Both groups showed significant results, the difference in between the groups is statistically insignificant.
PMCID: PMC3611658  PMID: 23559801
Aging; Drishti Hani; Jara; Medha Hani; Panchagavya; Twak Hani
2.  Fundamental approach in the management of Drava Bahula Amlapitta with Bhringaraja (Eclipta alba) 
Ayu  2011;32(4):512-517.
The disease Amlapitta has been selected for the clinical trials because it presents two type of manifestations depending upon the involvement of Agni (Ushnagunadhikya) and Jala (Dravagunadhikya) Mahabhuta. The present research work was focused at Drava Guna, with an aim to assess the efficacy of a drug with quality of Ruksha and Ushna predominance like Bhringaraja in treating Amlapitta with Pitta Drava Guna Vriddhi. Randomized open clinical trials were conducted on 22 patients of Amlapitta who were screened on the basis of clinical findings and allocated in to two groups. The criteria for selection were the signs and symptoms of Dravagunadhikya Amlapitta, irrespective of sex, religion, etc. Group A consisting of 15 cases received the trial drug Bhringaraja tablet (4 Tab. two times, 1 tablet=500 mg) and 7 cases in Group B received rice powder tablet as a placebo (4 Tab. two times, 1 tablet=500 mg) for 4 weeks. Special scoring pattern was adopted for the assessment of Amlapitta. Routine pathological tests such as blood, urine, stool, etc. were also carried out. In Group A, 55.33% patients showed marked improvement, whereas moderate improvement was observed in 26.67% patients. Complete cure was found in 06.67% of the patients and mild improvement in the chief complaints was observed in 13.33% patients. All the selected symptoms showed statistically significant results (P<0.01) except the Vidbheda in treated Group A, while in Group B, all symptoms showed statistically insignificant results except the Utklesha and Amlodgara. Total effect of the therapy showed statistically significant effect of the test drug. These results support the hypothesis
PMCID: PMC3361927  PMID: 22661846
Amlapitta; Bhringaraja; Drava; Ruksha; Ushna Guna
3.  A clinical trial of Pippali (Piper longum Linn.) with special reference to Abheshaja 
Ayu  2010;31(4):442-446.
The classification of Dravya has been undertaken in many ways, but according to the medicinal value, they are mainly divided into two - Bheshaja and Abheshaja. No study has been documented on Abheshaja to date as per the scholar's knowledge. Therefore, the present study was carried out to understand the concept of Abheshaja by a practical study. The drug Pippali (Piper Longum Linn.) has been contraindicated to be used for a longer duration. A clinical study was carried out on patients with Kaphaja Kasa, to evolve and assess if the drug acts as Abheshaja or not, and if yes, then under what circumstances. The patients of Kaphaja Kasa had been selected by the random sampling method. They were randomly divided into two groups - Group A and Group B. In Group A, test drug Pippali Churna was administered. Group B was a standard control group and Vasa Churna was given to this group. The dose of both the drugs was 4 g B.I.D. The result was assessed after three weeks of drug administration with the help of a specially prepared proforma. All the important hematological, biochemical, urine, and stool investigations were carried out. There was no adverse drug reaction (ADR) observed after the administration of Pippali in this particular study.
PMCID: PMC3202257  PMID: 22048536
Abheshaja; Adverse drug reaction; Pippali; Piper longum Linn.; Kaphaja Kasa

Results 1-3 (3)